L-депренил в лечении когнитивной функции у собак: литература
Cummings BJ, Head Е, Ruehl WW, et al: The canine as an animal model of human aging and dementia. Neurobiol Aging 17:259, 1996. A review of the evidence supporting the use of the aged canine as a model of human aging, including neuropathology, clinical aspects, and response to L- deprenyl therapy.
Hart BL, Hart LA: Selecting, raising, and caring for dogs to avoid problem aggression. J Am Vet Med Assoc 210:1129, 1997. Data are presented from a study on age-related behavioral changes in elderly dogs.
Head E, Hartley J, Kameka AM, et al: The effects of L-deprenyl on spatial short-term memory in young and aged dogs. Prog Neuropsychopharmacol Biol Psychiatry 20:515, 1996. Prospective study of spatial memory task performance in young and aged dogs given L-deprenyl or placebo, showing that L-deprenyl improved spatial memory in aged dogs.
Jenike MA, Albert MS: The dexamethasone suppression test in patients with presenile and senile dementia of the Alzheimer's type. J Am Geriatr Soc 32:441, 1984. Documents inadequate dexamethasone suppression in people with severe cognitive dysfunction or dementia.
Lupien S, LeCours A, Lussier I, et al: Basal Cortisol levels and cognitive deficits in human aging. J Neurosci 14:2893, 1994. Documents that altered Cortisol leveb precede and predict the development of cognitive dysfunction.
Morris JC: Diagnosis of Alzheimer's disease. In: Khachaturian ZS, Rade-baugh TS, eds: Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care. Boca Raton, FL: CRC Press, 1996, p 76. Discusses differentiating dementia from normal aging, the criteria for the clinical diagnosis of dementia of the Alzheimer's type and for definite histopathologic diagnosis of Alzheimer's disease.
Nieman LK, Cutler GB: Cushing's syndrome. In: DeGroot LJ, ed: Endocrinology, 3rd ed. Philadelphia: WB Saunders, 1995, p 1741. Discusses human Cushing's syndrome, including behavioral signs.
Olanow CW, Hauser RA, Gauger L, et al: The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38:771, 1995. This clinical trial confirms that L-deprenyl slows the clinical progression of neurodegenerative disease.
Pfizer Animal Health: Anipryl tablets package insert. Exton, PA: Pfizer Animal Health, 1997. Package insert for the veterinary formulation of L-deprenyl.
Ruehl WW, Hart BL: Canine cognitive dysfunction. In: Dodman NH, Shuster L, eds: Psychopharmacology of Animal Behavior Disorders. Maiden, MA: Blackwell Science, 1998, pp 283-304. Reviews recent studies in both dogs and human patients pertaining to age-related behavior changes, including prevalence, etiopathogenesis, results from neuropsychological laboratory studies, pharmacotherapy clinical trials, diagnosis, and management.
Ruehl WW, Bruyette DS, DePaoli A, et al: Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: Clinical presentation, cognitive testing, pathology and response to L-deprenyl therapy. Prog Brain Res 106:217, 1995. Discusses similarities of cognitive dysfunction between dogs and people and presents findings of a prospective clinical trial of L-deprenyl therapy in dogs with cognitive dysfunction.
Ruehl WW, Bruyette DS, Entriken TL, et al: Adrenal axis dysregulation in geriatric dogs with cognitive dysfunction. J Vet Intern Med 11:119, 1997 (abstract). Results of endocrine function tests from 249geriatric dogs with cognitive dysfunction confirm that hypothalamic-pituitary- adrenal (HPA) axis dysregulation occurs in the absence of typical physical signs of Cushing's syndrome or medical problems expected to activate the HPA axis.
Ruehl WW, Griffin D, Bouchard G, et al: Effects of L-deprenyl in cats in a one-month dose escalation study. Vet Pathol 33:621, 1996 (abstract). Results of a dose-escalation study to assess the toxicity of L-deprenyl in four cats.
Ruehl W, Hart B, Reisner I, et al: L-Deprenyl therapy for geriatric dogs with cognitive dysfunction (Abstract). J Vet Intern Med 12:206, 1998. Results of a clinical trial to assess the efficacy and safety of L-deprenyl in management of geriatric behavioral problems associated with cognitive function.
Shihabuddin L, Davis KL: Treatment of Alzheimer's disease. In: Khacha-turian ZS, Radebaugh TS, eds: Alzheimer's disease: Causes(s), Diagnosis, Treatment and Care. Boca Raton, FL: CRC Press, 1996, p 258. Discusses rationales and drugs for the treatment of dementia of the Alzheimer's type.
Tariot PN, Schneider LS, Patel SV, et al: Alzheimer's disease and L- deprenyl: Rationales and findings. In: Szelenyi I, ed: Inhibitors of Monoamine Oxidase B. Basel: Birkhauser Verlag, 1993, p 301. Summarizes rationales and clinical trial results of L-deprenyl treatment for dementia of the Alzheimer's type.
